Proactive Investors - Run By Investors For Investors

Cello Health Plc expects to hit expectations for 2018 after 'excellent year'

Mark Scott, chief executive of Cello Health plc (LON:CLL), spoke to Proactive London's Andrew Scott following the release of their pre-close trading statement for 2018.

Strong like-for-like growth at its big pharma consultancy division, known as health, offset a slower outcome from brand and marketing operation Signal.

The health division also saw good like-for-like gross profit growth and better-operating margins.

Meet Clinigen Group PLC, MaxCyte, Cello Health PLC, Oncimmune and Silence Therapeutics PLC at our event, London , 11 July 2019. Register here »
View full CLL profile View Profile

Cello Health PLC Timeline

April 11 2019
Big Picture
March 22 2019

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use